CerSci Therapeutics

CerSci Therapeutics is a clinical-stage biotechnology company with global rights to a novel combination of compounds for use in neurological disorders, including non-opioid therapies for acute and chronic pain. The lead development program is a unique Reactive Species Decomposition Accelerator (RSDAx), a first-in-class mechanism aimed at disrupting pathways that sensitize neurons to pain. The portfolio also includes other preclinical molecules, including brain-penetrant compounds with the potential for symptomatic and disease-modifying treatments in neurodegenerative diseases.